PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)

PHASE3CompletedINTERVENTIONAL
Enrollment

602

Participants

Timeline

Start Date

March 14, 2017

Primary Completion Date

August 21, 2023

Study Completion Date

August 21, 2023

Conditions
HIV-1 Infection
Interventions
DRUG

Pitavastatin

One tablet (4 mg) taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up.

DRUG

Placebos

One tablet taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up.

Trial Locations (31)

10010

Weill Cornell Chelsea CRS (7804), New York

10011

Weill Med. College of Cornell Univ., The Cornell CTU -Chelsea (7803), New York

10032

Columbia Physicians and Surgeons CRS (30329), New York

14642

University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787), Rochester

15213

Pittsburgh CRS (1001), Pittsburgh

19104

Hosp. of the Univ. of Pennsylvania CRS (6201), Philadelphia

21205

Johns Hopkins University CRS (201), Baltimore

27401

Greensboro CRS (3203), Greensboro

27516

Unc Aids Crs (3201), Chapel Hill

35294

Alabama CRS (31788), Birmingham

37204

Vanderbilt Therapeutics CRS (3652), Nashville

43210

The Ohio State Univ. AIDS CRS (2301), Columbus

44106

Case CRS (2501), Cleveland

45267

Univ. of Cincinnati CRS (2401), Cincinnati

60611

2701 Northwestern University CRS, Chicago

60612

Rush Univ. Med. Ctr. ACTG CRS (2702), Chicago

63110

Washington University CRS (2101), St Louis

75208

Trinity Health and Wellness Center CRS (31443), Dallas

77030

Houston AIDS Research Team (HART) CRS (31473), Houston

80045

University of Colorado Hospital CRS (6101), Aurora

90035

University of California, Los Angeles CARE Center CRS (601), Los Angeles

90502

Harbor-UCLA Med. Ctr. CRS (603), Torrance

92103

Ucsd, Avrc Crs (701), San Diego

94110

Ucsf Aids Crs (801), San Francisco

98104

University of Washington AIDS CRS (1401), Seattle

90033-1079

University of Southern California (1201), Los Angeles

02114

Massachusetts General Hospital (MGH) CRS (101), Boston

02115

Brigham and Women's Hosp. ACTG CRS (107), Boston

07103

New Jersey Medical School Clinical Research Center CRS (31786), Newark

02906

The Miriam Hospital (TMH) ACTG CRS (2951), Providence

00935

Puerto Rico-AIDS CRS (5401), San Juan

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

National Institute on Aging (NIA)

NIH

lead

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

NCT03070223 - PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332) | Biotech Hunter | Biotech Hunter